Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response

Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response. There were 61 patients wi...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of rheumatology Vol. 43; no. 8; p. 1566
Main Authors:	Bauhammer, Jutta, Blank, Norbert, Max, Regina, Lorenz, Hanns-Martin, Wagner, Ulrich, Krause, Dietmar, Fiehn, Christoph
Format:	Journal Article
Language:	English
Published:	Canada 01.08.2016
Subjects:	Adult Aged Autoantibodies - analysis Dermatomyositis - drug therapy Dermatomyositis - immunology Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Male Middle Aged Myositis - drug therapy Myositis - immunology Retrospective Studies Ribonucleoproteins - immunology Rituximab - therapeutic use Severity of Illness Index Treatment Outcome Young Adult INTERSTITIAL LUNG DISEASE ANTISYNTHETASE ANTIBODIES Ro52 Jo1 POLYMYOSITIS
ISSN:	0315-162X, 1499-2752, 1499-2752
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!